“The CBTTC is changing the way that we approach pediatric brain tumors.  By allowing researchers from across the world to collaborate and share critical biologic information about these tumors, the CBTTC has accelerated our ability to provide new treatments and hopefully a cure for childhood brain tumor patients.”

Dr. Derek Hanson, MD
Pediatric Hematology-Oncology
Hackensack University Medical Center
Hackensack, NJ

“CAVATICA helps to bring together pediatric brain cancer genomic data from many different sources in an accessible, easy to use platform so that researchers can nimbly answer specific genomic questions as new hypotheses arise in their work. It’s like putting all of the trees in one place so that one can now see the forest.”

Michelle Monje Deisseroth, MD, PhD
Assistant Professor of Neurology, and by courtesy, Neurosurgery, Pathology and Pediatrics,
Stanford University

“In my opinion, one of the strengths of the CBTTC is the focus on high-quality, longitudinal clinical data. Tumor tissue alone is not the answer– we need to also understand why some children respond to treatment and others do not. We need clinical data to pair with the tumor data. This is what sets the CBTTC apart from traditional tissue banks, and how as a physician-scientist I’ll be able to find more effective cancer treatments.”

Angela J. Waanders, MD, MPH
Attending Physician in the Neuro-Oncology Program and the Neurofibromatosis Program at Children’s Hospital of Philadelphia
Director of Clinical Research, Center for Data Driven Discovery in Biomedicine
Director of Operations, Children’s Brain Tumor Tissue Consortium

“Historically, we have failed to develop good and effective therapies because we did not understand the biology of many pediatric cancers.  Subsequent to advances in genome sequencing technologies, tumor biology (genome data) have been isolated and incompatible across platforms and academic institutions.  What CBTTC will offer is to unify data under one umbrella, making tumor biology accessible to all researchers.  This will empower research and will accelerate discovery.  Effective therapies are within reach once data is accessible.”

Javad Nazarian, PhD, MSC
Principal Investigator
The Children’s Research Institute at Children’s National Medical Center, Washington, DC

“The CBTTC has continued to grow over the past few years, and the infrastructure provides researchers an opportunity to merge detailed genomic data with accurate clinical data in every type of childhood brain tumor.  In the next few months, we will complete sequencing the entire bank and have that data available to share with our colleagues around the world —  increasing the pace of discovery for new treatments for our patients.  I could not be more proud to be working with this consortium.”

Rishi R. Lulla, MD
Associate Professor of Pediatrics
Ann & Robert H. Lurie Children’s Hospital of Chicago
Executive Chair of the Children’s Brain Tumor Tissue Consortium

“I am grateful to the CBTTC which provides rare patient samples and clinical and genomic sequencing information to empower my research to someday identify new therapies for patients with pediatric malignant gliomas. The unique infrastructure results from an organized partnership of patients/families, CBTTC scientists and physicians, philanthropists and researchers like me — who are all motivated to cure this devastating disease.”

Kristina Cole, MD/PhD.
Section of Neuro-Oncology
Division of Oncology
Children’s Hospital of Philadelphia

Dr. Cole learning to play a tune
from one of her patients.